Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy

Thymidine kinase 1 concentration and activity in metastatic breast cancer under CDK4/6 inhibitor therapy

Abstract We investigated whether TK1 concentration or activity in the blood, drawn at baseline and under therapy, might have value for therapy management in 110 hormone receptor-positive (HR+), HER2-negative (HER2-) metastatic breast cancer (mBC) patients treated with CDK4/6 inhibitors (CDK4/6i) and...

Full description

Saved in:
Bibliographic Details
Main Authors: Stefanos Ioannis Moukas, Merle Dohn, Catrin Lehnerdt, Anja Welt, Hans-Christian Kolberg, Oliver Hoffmann, Rainer Kimmig, Sabine Kasimir-Bauer, Corinna Keup
Format: Article
Language:English
Published: Nature Portfolio 2025-03-01
Series:Scientific Reports
Subjects:
Thymidine kinase 1
Progression-free survival
Breast cancer
Ribociclib
Palbociclib
Longitudinal studies
Online Access:https://doi.org/10.1038/s41598-025-95114-7
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1038/s41598-025-95114-7

Similar Items